NASDAQ · Financial Statements
AzurRx BioPharma, Inc. (AZRX) Financial Statements
$3.45
NASDAQ: AZRX
Market Cap $3.43M
Overview Financials Dividend
AzurRx BioPharma, Inc. most recently reported annual revenue of $0, a net loss of $7.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2018 2019 2020 2024 2025
Revenue $0 $0 $0 $0 $0 Operating Profit $-13.0M $-15.0M $-26.0M $-16.0M $-7.0M Net Profit $-14.0M $-15.0M $-33.0M $-18.0M $-7.0M EPS $-8.77 $-6.77 $-5.90 $-5.33 $-4.16 Op Margin — — — — -19540.0%
Balance Sheet (USD)
Metric 2018 2019 2020 2024 2025
Total Assets $7.0M $9.0M $0 $85.0M $49.0M Total Liabilities $3.0M $4.0M $0 $28.0M $20.0M Cash $1.0M $0 $0 $0 $1.0M Borrowings $0 $2.0M $0 $0 $2.0M
Cash Flow (USD)
Metric 2018 2019 2020 2024 2025
Operating Cash Flow $-11.0M $-14.0M $-11.0M $-9.0M $-6.0M Investing Cash Flow $0 $0 $0 $0 $0 Financing Cash Flow $12.0M $13.0M $33.0M $6.0M $6.0M Net Cash Flow $1.0M $-1.0M $6.0M $-4.0M $1.0M Free Cash Flow $-11.0M $-14.0M $-11.0M $-9.0M $-6.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.02 EV / EBITDA 3.11 FCF Yield -194.33% Quick Ratio 0.16 Interest Coverage 10.70 Return 1Y — Return 3Y — Return 5Y —
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .